Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
Launched by UNIVERSITY OF ULM · Feb 2, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying patients who are critically ill and have a specific type of infection caused by a bacteria called Pseudomonas aeruginosa (often just called PSA). The researchers want to understand how certain immune cells, called monocytes, behave in these patients. They are particularly interested in two types of monocytes: those that promote inflammation (M1) and those that help reduce inflammation (M2). By examining the balance between these two types, the study aims to find out if this influences how severe the infection is and how well patients recover.
To participate in this trial, individuals must be over 18 years old and must have a confirmed PSA infection along with severe illness. Unfortunately, patients who are expected to live less than 24 hours or are already participating in other studies cannot join. For those eligible, taking part in the trial will involve providing blood samples so that researchers can analyze the immune response to the infection. This study could help improve future treatments for patients with similar infections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \> 18 years
- • critically ill patients with sepsis
- • microbiologically proven infection with Pseudomonas aeruginosa
- Exclusion Criteria:
- • life expectancy \< 24 hours
- • participation in other studies
About University Of Ulm
The University of Ulm is a leading academic institution located in Germany, renowned for its commitment to cutting-edge research and innovation in the fields of medicine and health sciences. As a clinical trial sponsor, the university leverages its robust network of researchers and clinical experts to advance medical knowledge and improve patient outcomes. With a focus on interdisciplinary collaboration, the University of Ulm conducts comprehensive clinical studies that adhere to the highest ethical standards and regulatory guidelines. Through its research initiatives, the university aims to contribute significantly to the development of new therapies and treatment modalities, fostering a deeper understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ulm, , Germany
Patients applied
Trial Officials
Manfred Weiss, MD, MBA
Principal Investigator
University Ulm, University Hospital Ulm
Anne Sedlag, Biochemist
Principal Investigator
University Ulm, Institute of Microbiology and Biotechnology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials